Last week, the District Court of Northern Netherlands declared both Bedrocan Nederland B.V. and Bedrocan International B.V. bankrupt. Effectively ending the company’s two-decade run as the sole supplier of the Dutch medicinal cannabis program.

Bedrocan sought a suspension of payments in late September after its bank and the government couldn’t reach terms on outstanding debts, and the court granted that protection before converting it to bankruptcy two weeks later. The company’s largest site in Emmeloord produced around 7,000 kilos a year, with a smaller facility in Veendam adding roughly 1,200 kilos, per Omroep Flevoland’s reporting cited by MMJDaily. Around 70 people worked across those sites.

How Did a 40-Year-Old Cannabis Company End Up Here?

Bedrocan’s story stretches back to 1984, when it started as an indoor grower of chicory, herbs, and potted plants. It pivoted to medicinal cannabis in the 1990s and became, per MJBizDaily, “one of the oldest medical cannabis companies in the world.” It later became the first company globally to hold EU-GMP certification for medicinal cannabis, per Bedrocan’s own site, building a reputation for standardized products with consistent THC and CBD content batch after batch.

That consistency mattered because Bedrocan operated under a tightly controlled arrangement. According to company spokesperson Femke Starrenburg, the Office of Medicinal Cannabis (OMC or BMC) controlled which of the five approved varieties Bedrocan could grow and only placed orders as needed. This arrangement prevented Bedrocan from capitalizing on growing demand elsewhere, as regulations prohibited the company from selling directly to other distributors.

The real trouble started when the government’s contract with Bedrocan ended on January 1st 2026. The Dutch health ministry wants to move toward a less centralized model, amending the Opium Act so growers can sell straight to pharmacies instead of routing everything through the BMC. Health minister Sophie Hermans told parliament in July that this change won’t take effect until July 1, 2028. That left Bedrocan stuck in the middle: no government contract, and no legal path yet to sell directly to pharmacies.

During the suspension of payments, Bedrocan tried to get the ministry to agree to pay for and take delivery of remaining batches already produced, which could have secured financing to keep going. The ministry wouldn’t commit, according to Business of Cannabis, and bankruptcy became unavoidable.

What About Bedrocan’s Operations Outside the Netherlands?

The bankruptcy ruling applies only to the two Dutch entities. Bedrocan’s Danish and Canadian operations fall legally outside the filing, though the company is still working through the practical fallout.

In Denmark, Bedrocan Danmark ApS entered a formal restructuring process, called rekonstruktion. The company says production there continues as normal for now, but the Danish arm has historically depended on the Dutch parent through a cost-plus intercompany arrangement, so the bankruptcy in the Netherlands inevitably complicates its finances. Danish cannabis company Stenocare, which distributes Bedrocan products under the CannGros brand in Denmark, confirmed in an October 2 update that it’s now seeking alternative supply for 2027.

Stenocare CEO Thomas Skovlund Schnegelsberg argued that Dutch authorities could have prevented the collapse if they had set new rules earlier or simply extended the export arrangement into 2027, as they had done before.

On the Canadian side, Bedrocan returned to production in Scarborough, Ontario, in 2024, according to MJBizDaily, and that facility isn’t part of the Dutch bankruptcy. Still, it’s worth noting the Danish site, not the Canadian one, has handled the bulk of international supply to countries like Denmark, Italy, and Germany in recent years.

What Happens to the Roughly 7,000 Dutch Patients Who Rely on This Cannabis?

This is the part that worries patient groups the most. In the Netherlands, doctors prescribe medicinal cannabis to around 7,000 people to treat conditions such as multiple sclerosis, severe chronic pain, treatment-resistant epilepsy, and to support palliative care. The BMC built up a stockpile before the contract ended, but that supply has a finite shelf life.

Dutch cannabis typically stays usable for about a year after harvest, which means current stock could run out around September 2027, roughly ten months before the expected Opium Act amendment takes effect in mid-2028. The health ministry has acknowledged its own reserves won’t fully bridge that gap.

One product raises particular concern: Bedrolite. This CBD-dominant oil treats Dravet syndrome and Lennox-Gastaut syndrome, two severe forms of childhood epilepsy, and only the Netherlands produces it. The curators currently control hundreds of kilos worth millions of euros, all frozen in storage. Because Bedrolite falls under the Opium Act, no one can sell or distribute it without approval from the BMC.Setting up Bedrolite production in Denmark instead would take at least six months, assuming a buyer or operator steps forward to do it.

In August, patient advocacy group Hollandbio told a parliamentary health committee that government delays had “entirely self-created” the shortage. The Dutch MS association has also separately warned Hermans that long-term patients often depend on one specific variety and cannot simply switch to a different product without medical guidance.

What Is the Dutch Government’s Plan to Close the Supply Gap?

The health ministry’s stated plan is to shift toward imported medicinal cannabis through a European tender process during 2027, inviting outside producers to supply the Dutch market in Bedrocan’s place, according to DutchNews. As of now, no alternate supplier has been named.

The government aims to match the THC and CBD content of imported products as closely as possible to what patients are used to. Bedrocan’s flowers include THC-dominant varieties with up to 22% THC and CBD-dominant varieties with up to 9% CBD, setting the benchmark for this comparison. But patient groups remain skeptical that imports will be straightforward substitutes, especially for people who’ve relied on one variety for years.

There’s also a financial angle. Government figures suggest the loss of Bedrocan’s export income costs the state roughly 8 million euros a year, based on parliamentary documents referenced by Business of Cannabis. And the larger European market context matters here too: Germany remains the continent’s largest importer of medical cannabis, with Canada supplying the bulk of that demand (about 93,000 kg in 2025) and Portugal a distant second at 55,000 kg. Dutch exports to Germany, by contrast, dropped from 17.9% of German imports in 2021 to just 1.2% in 2025, showing how much ground Bedrocan had already lost before the bankruptcy.

What to Watch Next in Dutch and European Medicinal Cannabis

The next real signal will come from the curators’ first public report, expected in early January 2027, which should clarify whether any buyer can acquire Bedrocan’s Dutch assets or frozen inventory with BMC approval. A deal tied to the Danish restructuring is one possible path forward, as is a direct release of stock by the Dutch state, though neither has been confirmed.

Meanwhile, larger cannabis companies are already repositioning around the gap left in European supply. Canadian producers Aurora Cannabis and Tilray Brands have been expanding their European footprints, and Curaleaf completed a buyout of German firm Four 20 Pharma earlier this year. None of that directly solves the Dutch patient shortage, but it shows how quickly the rest of the market is moving while the Netherlands works out its own supply chain.

For now, the most pressing question is a human one: how patients who’ve depended on a specific standardized product for years will be guided through a transition to something else, and whether that transition happens before the clock runs out on existing stock.

Frequently Asked Questions

---

• MedMen a Once Cannabis Giant, Announces Bankruptcy Proceedings
• Dutch Treat Cannabis Strain
• Breeding the Culture: Henk van Dalen and Dutch Passion
• The Netherlands Solved the Back Door. Now Big Tobacco Is Using the Front
• Dutch Cannabis Trial Cuts Flower Prices, Not Reported Use